$PPCB
Propanc Biopharma, Inc. Stock $ppcb

$ppcb Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000149315222027033 Filed on September 28, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$471.5K	$490.8K	$1.735M
YoY Change	7.29%	-23.53%	9.72%
% of Gross Profit
Research & Development	$101.3K	$108.4K	$256.1K
YoY Change	117.67%	27.38%	10.86%
% of Gross Profit
Depreciation & Amortization	$473.00	$490.00	$1.993K
YoY Change	-7.25%	-5.77%	0.15%
% of Gross Profit
Operating Expenses	$572.8K	$599.2K	$1.991M
YoY Change	17.86%	-17.57%	9.86%
Operating Profit	-$572.8K		-$1.991M
YoY Change	17.86%		9.86%
Interest Expense	$162.8K	-$287.8K	$568.8K
YoY Change	-3622.77%	431.49%	-233.16%
% of Operating Profit
Other Income/Expense, Net	-$44.47K		-$722.2K
YoY Change	860.78%
Pretax Income	-$617.3K	-$904.5K	-$2.713M
YoY Change	25.81%	15.94%	26.82%
Income Tax		$270.00	-$54.98K
% Of Pretax Income
Net Earnings	-$617.3K	-$904.8K	-$2.658M
YoY Change	25.81%	16.14%	31.2%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00		-$0.05
Diluted Earnings Per Share	-$1.303K	-$6.950K	-$38.96K
COMMON SHARES
Basic Shares Outstanding	677.2M shares		68.22M shares
Diluted Shares Outstanding	473.6K shares		68.22K shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.40K	$4.070K	$4.070K
YoY Change	-57.66%	80.09%	80.09%
Cash & Equivalents	$19.40K	$4.067K
Short-Term Investments
Other Short-Term Assets	$15.77K	$8.620K	$8.620K
YoY Change	88.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$37.86K	$15.03K	$15.03K
YoY Change	-32.88%	127.73%	127.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.437K	$2.023K	$64.55K
YoY Change	-59.97%	-52.51%	1415.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.930K	$2.080K	$2.080K
YoY Change	-10.65%	-7.56%	-7.56%
Total Long-Term Assets	$56.39K	$66.62K	$66.62K
YoY Change	879.03%	924.94%	924.92%
TOTAL ASSETS
Total Short-Term Assets	$37.86K	$15.03K	$15.03K
Total Long-Term Assets	$56.39K	$66.62K	$66.62K
Total Assets	$94.25K	$81.65K	$81.65K
YoY Change	51.61%	523.29%	523.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$899.2K	$943.0K	$943.0K
YoY Change	8.84%	-5.92%	-5.92%
Accrued Expenses	$860.4K	$902.5K	$902.5K
YoY Change	5.65%	-31.14%	-31.14%
Deferred Revenue
YoY Change
Short-Term Debt	$961.2K	$1.035M	$1.035M
YoY Change	50.67%	52.25%	52.25%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.822M	$3.063M	$3.063M
YoY Change	19.15%	-0.57%	-0.57%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$39.36K	$42.32K	$42.32K
YoY Change
Total Long-Term Liabilities	$39.36K	$42.32K	$42.32K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.822M	$3.063M	$3.063M
Total Long-Term Liabilities	$39.36K	$42.32K	$42.32K
Total Liabilities	$2.862M	$3.105M	$3.105M
YoY Change	20.81%	0.8%	0.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$62.56M	-$61.56M
YoY Change		5.77%
Common Stock	$677.2K	$220.4K
YoY Change		1467.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$46.48K	$46.48K
YoY Change		0.0%
Treasury Stock Shares	1.000 shares	1.000 shares
Shareholders Equity	-$2.768M	-$3.024M	-$3.024M
YoY Change
Total Liabilities & Shareholders Equity	$94.25K	$81.65K	$81.65K
YoY Change	51.61%	523.29%	523.28%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$617.3K	-$904.8K	-$2.658M
YoY Change	25.81%	16.14%	31.2%
Depreciation, Depletion And Amortization	$473.00	$490.00	$1.993K
YoY Change	-7.25%	-5.77%	0.15%
Cash From Operating Activities	-$509.3K	-$411.0K	-$1.436M
YoY Change	4.63%	73.94%	25.41%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$99.29K	$99.29K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$494.2K	374.3K	$1.491M
YoY Change	13.61%	49.72%	40.9%
NET CHANGE
Cash From Operating Activities	-$509.3K	-411.0K	-$1.436M
Cash From Investing Activities
Cash From Financing Activities	$494.2K	374.3K	$1.491M
Net Change In Cash	$15.33K	-36.70K	$1.812K
YoY Change	-129.62%	-367.49%	-102.08%
FREE CASH FLOW
Cash From Operating Activities	-$509.3K	-$411.0K	-$1.436M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	PPCB	Discounts Related To Derivative Liability DiscountsRelatedToDerivativeLiability		usd
CY2021	PPCB	Operating Lease Rightofuse Asset And Operating Lease Liability Recorded Pursuant To Asc842 OperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityRecordedPursuantToAsc842		usd
CY2022	dei	Entity File Number EntityFileNumber	000-54878
CY2022	PPCB	Reversal Of Common Stock Issuable And Put Premium Due To Cancellation Of Conversions Of Convertible Debt And Accrued Interest ReversalOfCommonStockIssuableAndPutPremiumDueToCancellationOfConversionsOfConvertibleDebtAndAccruedInterest		usd
CY2022	PPCB	Accounts Payable Reclass To Convertible Notes AccountsPayableReclassToConvertibleNotes		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	dei	Entity Registrant Name EntityRegistrantName	PROPANC BIOPHARMA, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0662986
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	302
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	6 Butler Street
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022	PPCB	Weighted Average Fair Value Of Options Granted During Period WeightedAverageFairValueOfOptionsGrantedDuringPeriod	P0Y
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2021	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceIssued
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2021	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceForfeited
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2021	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExpired
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceIssued
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2022	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceForfeited
CY2022	PPCB	Stock Issued During Period Value Of Common Stock For Alternate Cashless Exercise Of Warrants StockIssuedDuringPeriodValueOfCommonStockForAlternateCashlessExerciseOfWarrants		usd
CY2022	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants DeemedDividendUponAlternateCashlessExerciseOfWarrants		usd
CY2022	PPCB	Gain From Settlement Of Debt Net GainFromSettlementOfDebtNet		usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Camberwell, VIC
CY2022	dei	Entity Address Country EntityAddressCountry	AU
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets		usd
CY2022	PPCB	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent		usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	3124
CY2022	dei	City Area Code CityAreaCode	61 03
CY2022	dei	Local Phone Number LocalPhoneNumber	9882 0780
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	PPCB	Common Stock Issued For Offering Cost Applied Against Proceeds Received CommonStockIssuedForOfferingCostAppliedAgainstProceedsReceived		usd
CY2021	PPCB	Supplemental Disclosure Of Non Cash Investing And Financing Activities Subscription Receivable SupplementalDisclosureOfNonCashInvestingAndFinancingActivitiesSubscriptionReceivable		usd
CY2022	PPCB	Discounts Related To Derivative Liability DiscountsRelatedToDerivativeLiability		usd
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001517681
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent		usd
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2021Q2	PPCB	Subscription Receivable SubscriptionReceivable		usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	PPCB	Gain From Settlement Of Debt Net GainFromSettlementOfDebtNet		usd
CY2021	PPCB	Issuance Of Common Stock For Cashless Exercise Of Warrants IssuanceOfCommonStockForCashlessExerciseOfWarrants		usd
CY2021	PPCB	Stock Issued During Period Value Vested Restricted Stock Units StockIssuedDuringPeriodValueVestedRestrictedStockUnits		usd
CY2021	PPCB	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2022	PPCB	Stock Issued During Period Value Of Common Stock For Offering Cost StockIssuedDuringPeriodValueOfCommonStockForOfferingCost		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2022	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExpired
CY2022Q2	PPCB	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2021Q2	PPCB	Less Office Lease Current Portion LessOfficeLeaseCurrentPortion		usd
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	1519637	usd
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	677177717	shares
CY2022	dei	Auditor Firm AuditorFirmId	106
CY2022	dei	Auditor Name AuditorName	SALBERG & COMPANY, P.A
CY2022	dei	Auditor Location AuditorLocation	Boca Raton, Florida
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4067	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2255	usd
CY2022Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2342	usd
CY2021Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	4341	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8621	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	15030	usd
CY2021Q2	us-gaap	Assets Current AssetsCurrent	6596	usd
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2075	usd
CY2021Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2250	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	62523	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2023	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4255	usd
CY2022Q2	us-gaap	Assets Assets	81651	usd
CY2021Q2	us-gaap	Assets Assets	13101	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	943023	usd
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1002335	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	466115	usd
CY2021Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	892151	usd
CY2022Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	984260	usd
CY2021Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	624583	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	20605	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	151262	usd
CY2021Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	54220	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	30746	usd
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	33347	usd
CY2022Q2	PPCB	Loan From Former Director Related Party LoanFromFormerDirectorRelatedParty	51171	usd
CY2021Q2	PPCB	Loan From Former Director Related Party LoanFromFormerDirectorRelatedParty	55500	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	415799	usd
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	418538	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3062981	usd
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3080674	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	42319	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	42319	usd
CY2022Q2	us-gaap	Liabilities Liabilities	3105300	usd
CY2021Q2	us-gaap	Liabilities Liabilities	3080674	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500005	shares
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500005	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	220350921	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	220350921	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14055393	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14055393	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	220351	usd
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	14056	usd
CY2022Q2	PPCB	Common Stock Issuable Shares CommonStockIssuableShares	19597024	shares
CY2021Q2	PPCB	Common Stock Issuable Shares CommonStockIssuableShares	59	shares
CY2022Q2	PPCB	Common Stock Issuable CommonStockIssuable	19597	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57124982	usd
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	54074110	usd
CY2022Q2	PPCB	Subscription Receivable SubscriptionReceivable	-23758	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1234549	usd
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1085204	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61557893	usd
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58199466	usd
CY2022Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	1	shares
CY2021Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	1	shares
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	46477	usd
CY2021Q2	us-gaap	Treasury Stock Value TreasuryStockValue	46477	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3023649	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-3067573	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	81651	usd
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13101	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1706452	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1553075	usd
CY2022	PPCB	Occupancy Net Related Party OccupancyNetRelatedParty	28366	usd
CY2021	PPCB	Occupancy Net Related Party OccupancyNetRelatedParty	28112	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	256052	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	230956	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1990870	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	1812143	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1990870	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-1812143	usd
CY2022	us-gaap	Interest Expense InterestExpense	568798	usd
CY2021	us-gaap	Interest Expense InterestExpense	449457	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	5613	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	1	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-99111	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-8186	usd
CY2021	PPCB	Gain From Settlement Of Debt Net GainFromSettlementOfDebtNet	49319	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-17503	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	50607	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-42395	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	30497	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-722194	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-327219	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2713064	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2139362	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-54977	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-113415	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2658087	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2025947	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	700340	usd
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	391749	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3358427	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2417696	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68218701	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3032612	shares
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3358427	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2417696	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	149345	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-182467	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	149345	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-182467	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3209082	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2600163	usd
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-3641425	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1239075	usd
CY2021	PPCB	Reversal Of Common Stock Issuable Due To Cancellation Of Conversions Of Convertible Debt And Accrued Interest ReversalOfCommonStockIssuableDueToCancellationOfConversionsOfConvertibleDebtAndAccruedInterest	-20016	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	125572	usd
CY2021	PPCB	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	776044	usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	590504	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	-11785	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	82872	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-182467	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2025947	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-3067573	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99285	usd
CY2022	PPCB	Stock Issued During Period Value Issuance Of Common Stock For Conversion Of Convertible Debt Conversion Fee And Accrued Interest StockIssuedDuringPeriodValueIssuanceOfCommonStockForConversionOfConvertibleDebtConversionFeeAndAccruedInterest	657125	usd
CY2022	PPCB	Stock Issued During Period Value Of Common Stock For Services And Accrued Expenses StockIssuedDuringPeriodValueOfCommonStockForServicesAndAccruedExpenses	763065	usd
CY2022	PPCB	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	625001	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	335677	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	72513	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	149345	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2658087	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3023649	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2658087	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2025947	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	314626	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	125572	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-42395	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	30497	usd
CY2022	us-gaap	Depreciation Depreciation	1993	usd
CY2021	us-gaap	Depreciation Depreciation	1993	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	47971	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	136527	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-99111	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-8186	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-17503	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	50607	usd
CY2021	PPCB	Gain From Settlement Of Debt Net GainFromSettlementOfDebtNet	49319	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	72513	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	82872	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	2250	usd
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	16500	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3678	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-452308	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-200410	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1660	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2147	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8620	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	18870	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	178311	usd
CY2021	PPCB	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	3695	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	29907	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	33134	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	65017	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	152861	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	63878	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	80582	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3277	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1436304	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1145264	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	766500	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	325000	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	43000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	99285	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	625001	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	776044	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1490786	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1058044	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-52670	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22468	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1812	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-64752	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2255	usd
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	67007	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4067	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2255	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2392	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	13621	usd
CY2022	PPCB	Common Stock Issued For Offering Cost Applied Against Proceeds Received CommonStockIssuedForOfferingCostAppliedAgainstProceedsReceived	20000	usd
CY2022	PPCB	Supplemental Disclosure Of Non Cash Investing And Financing Activities Subscription Receivable SupplementalDisclosureOfNonCashInvestingAndFinancingActivitiesSubscriptionReceivable	23758	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	335677	usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	590504	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	635303	usd
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1142205	usd
CY2022	PPCB	Operating Lease Rightofuse Asset And Operating Lease Liability Recorded Pursuant To Asc842 OperatingLeaseRightofuseAssetAndOperatingLeaseLiabilityRecordedPursuantToAsc842	66201	usd
CY2021	PPCB	Reversal Of Common Stock Issuable And Put Premium Due To Cancellation Of Conversions Of Convertible Debt And Accrued Interest ReversalOfCommonStockIssuableAndPutPremiumDueToCancellationOfConversionsOfConvertibleDebtAndAccruedInterest	31801	usd
CY2021	PPCB	Accounts Payable Reclass To Convertible Notes AccountsPayableReclassToConvertibleNotes	25000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	448440	usd
CY2022	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants1 DeemedDividendUponAlternateCashlessExerciseOfWarrants1	700340	usd
CY2021	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants1 DeemedDividendUponAlternateCashlessExerciseOfWarrants1	391749	usd
CY2020Q4	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	one-for-one thousand
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3001500005	shares
CY2022Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	782886	usd
CY2021Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	796509	usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10294432	usd
CY2021Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9955098	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10294432	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zMxL0R7AqlEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zaAi3RBbCYo1">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with the accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of beneficial conversion features on convertible debt, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPANC BIOPHARMA, INC. AND SUBSIDIARY</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2022 and 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span> </p>
CY2022Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.6915	pure
CY2021Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.7500	pure
CY2021Q2	PPCB	Deferred Tax Assets Non Cash Interest DeferredTaxAssetsNonCashInterest	687529	usd
CY2022Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	293260	usd
CY2021Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	259743	usd
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1267671	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	182467	usd
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1085204	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	149345	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1234549	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9955098	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2021Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	4198	usd
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	10200000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.26	pure
CY2022Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2342	usd
CY2021Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	4341	usd
CY2022	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_846_eus-gaap--DerivativesReportingOfDerivativeActivity_zmFjogOyJca5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zhRKRD8D3bWf">Derivative Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC Topic 815, <i>Derivatives and Hedging</i> (“ASC Topic 815”), establishes accounting and reporting standards for derivative instruments and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value. Gains or losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion or payoff of debt, the Company records the fair value of the conversion shares, removes the fair value of the related derivative liability, removes any discounts and records a net gain or loss on debt extinguishment. On July 1, 2019 the Company adopted ASU 2017-11 under which down-round Features in Financial Instruments will no longer cause derivative treatment. The Company applied the modified prospective method of adoption. There were no cumulative effects on adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10751607	usd
CY2022Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	170435	usd
CY2021Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	197604	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	256052	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	230956	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-54977	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-113415	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-113415	usd
CY2022	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance.
CY2022	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.0499	pure
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	127167864	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12538419	shares
CY2022Q2	PPCB	Deferred Tax Assets Warrant Derivative Liability DeferredTaxAssetsWarrantDerivativeLiability	7403	usd
CY2021Q2	PPCB	Deferred Tax Assets Warrant Derivative Liability DeferredTaxAssetsWarrantDerivativeLiability	7403	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2658087	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1436304	usd
CY2022Q2	PPCB	Working Capital Deficit WorkingCapitalDeficit	3047951	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3023649	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61557893	usd
CY2022Q2	PPCB	Deferred Tax Liabilities Gain On Extinguishment Of Debt DeferredTaxLiabilitiesGainOnExtinguishmentOfDebt	259470	usd
CY2021Q2	PPCB	Deferred Tax Liabilities Gain On Extinguishment Of Debt DeferredTaxLiabilitiesGainOnExtinguishmentOfDebt	277614	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	28623	usd
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	28623	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	26600	usd
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24368	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2023	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4255	usd
CY2022	us-gaap	Depreciation Depreciation	1993	usd
CY2021	us-gaap	Depreciation Depreciation	1993	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	363873	usd
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	342464	usd
CY2022Q2	PPCB	Deferred Tax Assets Prepaid Investor Services DeferredTaxAssetsPrepaidInvestorServices	427318	usd
CY2021Q2	PPCB	Deferred Tax Assets Prepaid Investor Services DeferredTaxAssetsPrepaidInvestorServices	444411	usd
CY2022Q2	PPCB	Deferred Tax Assets Non Cash Interest DeferredTaxAssetsNonCashInterest	709936	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	30746	usd
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	33347	usd
CY2022Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	352981	usd
CY2021Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	321291	usd
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	644980	usd
CY2021Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	400128	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	31669	usd
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	6139	usd
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	57822	usd
CY2021Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	34098	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	313127	usd
CY2021Q2	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	196496	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	984260	usd
CY2021Q2	us-gaap	Long Term Debt LongTermDebt	624583	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	47971	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	136527	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	335677	usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	590504	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-54977	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	105420	shares
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	4262	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	6553	usd
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	6815	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8759357	usd
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8546920	usd
CY2022Q2	PPCB	Deferred Tax Assets Foreign Exchange Loss DeferredTaxAssetsForeignExchangeLoss	-39379	usd
CY2021Q2	PPCB	Deferred Tax Assets Foreign Exchange Loss DeferredTaxAssetsForeignExchangeLoss	-39379	usd
CY2022Q2	PPCB	Deferred Tax Assets Revalue Of Derivative Liability DeferredTaxAssetsRevalueOfDerivativeLiability	460772	usd
CY2021Q2	PPCB	Deferred Tax Assets Revalue Of Derivative Liability DeferredTaxAssetsRevalueOfDerivativeLiability	439958	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	84028	usd
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	51481	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11077318	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q2	PPCB	Number Of Preferred Stock Authorized Shares NumberOfPreferredStockAuthorizedShares	1500005	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3001500005	shares
CY2020Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-one thousand (1:1,000)
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500005	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	99285	usd
CY2022Q2	PPCB	Subscription Receivable SubscriptionReceivable	-23758	usd
CY2022Q3	PPCB	Subscription Receivable SubscriptionReceivable	-23758	usd
CY2020Q3	PPCB	Unissued Shares Conversion UnissuedSharesConversion	24427	shares
CY2020Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	19600	usd
CY2020Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	416	usd
CY2020Q4	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	11785	usd
CY2020Q4	PPCB	Due To Equity Conversion DueToEquityConversion	31801	usd
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	95000	usd
CY2021Q2	us-gaap	Interest Payable Current InterestPayableCurrent	3000	usd
CY2021Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	178368	usd
CY2021Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	80368	usd
CY2021Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	130975	usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	590504	usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	8000	usd
CY2022Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	28572	usd
CY2022Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	19572	usd
CY2022Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	2069	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	335677	usd
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	56799716	shares
CY2022	PPCB	Deemed Dividend DeemedDividend	700340	usd
CY2021	PPCB	Deemed Dividend DeemedDividend	391749	usd
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	60	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	76370
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	3750000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	59	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13730
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	59	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4533
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	59	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4531
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M17D
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	72513	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	82872	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	151170	shares
CY2020Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding	150.00
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	29841	shares
CY2021	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExercised	26.15
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	121329	shares
CY2021Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding	179.63
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	15909	shares
CY2022	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExercised	42.86
CY2022Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding	200.27
CY2022Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	76671	shares
CY2022Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisable	275.37
CY2022	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P0Y9M7D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	105420	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	105420	shares
CY2022Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	76671	shares
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	776044	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	625001	usd
CY2022	PPCB	Litigation Penalty Amount LitigationPenaltyAmount	30000	usd
CY2022Q2	PPCB	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	66201	usd
CY2021Q2	PPCB	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	48662	usd
CY2022Q2	PPCB	Accumulated Reduction AccumulatedReduction	-3678	usd
CY2021Q2	PPCB	Accumulated Reduction AccumulatedReduction	-48662	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	62523	usd
CY2022Q2	PPCB	Office Lease Liability OfficeLeaseLiability	66201	usd
CY2021Q2	PPCB	Office Lease Liability OfficeLeaseLiability	48662	usd
CY2022Q2	PPCB	Reduction Of Lease Liability ReductionOfLeaseLiability	-3277	usd
CY2021Q2	PPCB	Reduction Of Lease Liability ReductionOfLeaseLiability	-48662	usd
CY2022Q2	PPCB	Less Office Lease Current Portion LessOfficeLeaseCurrentPortion	-20605	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	42319	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	24894	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	24894	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	20745	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7609	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	62924	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M7D
CY2019	PPCB	Payment For Services PaymentForServices	31754
CY2019	PPCB	Payment For Services PaymentForServices	36117	usd
CY2021	PPCB	Payment For Services PaymentForServices	28493
CY2021	PPCB	Payment For Services PaymentForServices	24043	usd
CY2020Q4	PPCB	Royalties Percentage RoyaltiesPercentage	0.02	pure
CY2022	us-gaap	Payments For Rent PaymentsForRent	28366	usd
CY2021	us-gaap	Payments For Rent PaymentsForRent	28112	usd
CY2022	PPCB	Bonus Payable BonusPayable	144166	aud
CY2022	PPCB	Bonus Payable BonusPayable	99691	usd
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	54000	aud
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	37341	usd
CY2021Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	135000	aud
CY2021Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	101250	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	73500	usd
CY2022Q2	us-gaap	Share Price SharePrice	0.0037
CY2022Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	151262	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	151262	usd
CY2021Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	54220	usd
CY2021Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	54220	usd
CY2020Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	177009	usd
CY2021	PPCB	Gain On Debt Extinguishment GainOnDebtExtinguishment	130975	usd
CY2021	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	8186	usd
CY2021Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	54220	usd
CY2022	PPCB	Gain On Debt Extinguishment GainOnDebtExtinguishment	2069	usd
CY2022	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	99111	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	151262	usd

Files In Submission

Name	View Source	Status
0001493152-22-027033-index-headers.html	Edgar Link	pending
0001493152-22-027033-index.html	Edgar Link	pending
0001493152-22-027033.txt	Edgar Link	pending
0001493152-22-027033-xbrl.zip	Edgar Link	pending
aud_001.jpg	Edgar Link	pending
ex21.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ppcb-20220630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ppcb-20220630_cal.xml	Edgar Link	unprocessable
ppcb-20220630_def.xml	Edgar Link	unprocessable
ppcb-20220630_pre.xml	Edgar Link	unprocessable
ppcb-20220630_lab.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PPCB
Propanc Biopharma, Inc. Stock $ppcb

2022 Q3 Form 10-K Financial Statement

#000149315222027033 Filed on September 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPCB Propanc Biopharma, Inc. Stock $ppcb

2022 Q3 Form 10-K Financial Statement

#000149315222027033 Filed on September 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPCB
Propanc Biopharma, Inc. Stock $ppcb